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ABSTRACT
Secreted acid proteinases (SAP) constitute an important group of virulence factors in Candida albicans. In the
present work, an acid proteinase from C. albicans was sequentially purified from the supernatant of a yeast
culture by precipitation with ammonium sulfate, ion exchange chromatography, and molecular exclusion chro-
matography, yielding a specific enzymatic activity of 204.1 IU/mg on bovine serum albumin (BSA). The mo-
lecular mass of the purified proteinase was estimated at 43 kd after exclusion chromatography and at 41 kd
by nondenaturating sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified
proteinase was able to degrade BSA at pH 2.5, but was not active on collagen, and it was significantly inhib-
ited by pepstatin A. The immunization of BALB/c mice with the purified proteinase and later fusion of their
spleen cells with myeloma cells resulted in 19 monoclonal antibody secreting hybridomas (MAbs) capable of
detecting SAP in enzyme-linked immunosorbent assay (ELISA) assays. All MAbs obtained are isotype IgG1
kappa () immunoglobulins and develop a 41 kd protein band by Western blot (WB) in samples of SAP ob-
tained from C. albicans (12-A) and C. dubliniensis (strain 778) crude extracts. The anti-SAP MAbs were used
in capture ELISA and two combinations of these antibodies proved suitable for SAP detection, that is, MAP1
(1B1B3) or MAP2 (2D2C10) as coat antibodies, and biotinylated MAP3 (2A6E8) as detect antibody. Capture
ELISA using these sets of MAbs detected over 32 ng/mL protein in purified SAP samples as well as in crude
C. albicans and C. dubliniensis extracts. The results herein obtained allow for the prediction of how this set
of antibodies can be useful for SAP detection in biologic specimens.
INTRODUCTION
DIFFERENT SPECIES OF FUNGI can cause infection in humansin a disseminated manner,(1) and their incidence has in-
creased in recent years as the number of immunocompromised
patients grows with the use of wide-spectrum antimycotic
agents, as well as in patients subjected to invasive surgical pro-
cedures.(2) The genus Candida comprises an extensive group
of yeasts (C. albicans, C. tropicalis, C. glabrata, C. parap-
silosis, C. krusei, C. guilliermondii, and C. dubliniensis) that
are present in the oral cavity, digestive tract, and vascular sys-
tem of humans, which maintain these microbial agents as com-
mensals. However, local or systemic alterations in the organ-
ism, together with the various virulence factors of these mi-
croorganisms, encourage the development of their pathogenic
action, causing infectious diseases such as candidiasis.(1,3) Lit-
tle is known about the mechanisms by which microorganisms
of the genus Candida cause disease in debilitated patients. How-
ever, some virulence factors seem to contribute to the patho-
genicity of this yeast species, such as adhesins, which recog-
nize host biomolecules, promoting the yeast’s adherence to the
cell surface, especially in mucosae; phenotypic variability
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(switching) involved in the reversible transition between the
unicellular and filamentous forms; and hydrolytic toxins and
exoenzymes, such as aspartyl proteases, which favor dissemi-
nation of the fungus.(4–6) Additionally, phenotypic switching is
accompanied by changes in antigen expression (antigen vari-
ability), morphology of the colony, affinity with the tissues in
which these microorganisms are found, thus allowing flexibil-
ity in the adaptation of yeasts to the hostile conditions imposed
by the host and by the clinical treatment of infection.(3)
C. albicans is considered one of the most important patho-
gens in the genus Candida,(7) but many patients may harbor
more than one species simultaneously, especially immuno-
compromised patients.(5) Currently, the diagnosis of these mi-
croorganisms and treatment of bearers is very difficult. The
identification of different Candida species can be made by
means of biochemical tests, conducted in media designed es-
pecially for grouping certain species of the fungus. The CHRO-
Magar Candida medium separates Candida species into four
groups: (1) C. albicans and C. dubliniensis; (2) C. tropicalis;
(3) C. krusei; and (4) other species.(6) The formation of chlamy-
dospores in rice agar-Tween 80 is a trait exhibited by C. albi-
cans and C. dubliniensis but not by the other species of the fun-
gus.(8) C. dubliniensis is a species highly related to C. albicans
both phenotypically and genetically. These are the only species
in the genus that, in addition to the formation of pseudohyphae,
can also form germ tubes and true hyphae. The differentiation
between C. albicans and C. dubliniensis, however, can be ob-
tained by growing the first at 45°C(9) or by polymerase chain
reaction (PCR).(10) With regard to their sensitivity to antimy-
cotic agents, there have been reports of C. albicans, C. krusei,
and C. dubliniensis isolates resistant to fluconazole, a wide-
spectrum antimycotic agent generally administered for can-
didiasis treatment.(11,12)
The first description of C. dubliniensis as a distinct species
from C. albicans was made in samples obtained from oral in-
fections in human immunodefiency virus (HIV)-infected and
acquired immune deficiency syndrome (AIDS) patients.(8) Sub-
sequent investigations in C. albicans culture collections re-
vealed that approximately 2% of the yeasts were actually C.
dubliniensis isolates.(11) Since then, C. dubliniensis has been
found around the world associated with superficial or systemic
infections.(13) Because of its similarity with C. albicans, dif-
ferentiation methods for these two species have been exten-
sively investigated. Pal’s Agar culture medium, based on the
use of sunflower seed extract (Helianthus annus), seems to be
the most suitable medium to differentiate between both Can-
dida species.(14) More sophisticated methods have also been
used to evaluate the differences and similarities that exist be-
tween these two Candida species, such as PCR, DNA finger-
printing, and pulsed-field gel electrophoresis; these, however,
are costly and time-consuming methods, and are difficult to ap-
ply for a large number of isolates.(15) Together, these methods
allowed the verification that homologous C. albicans SAP
genes are found in C. dubliniensis yeasts. However, both species
have been shown to be significantly different in aspects such
as sensitivity to antimycotic agents, adherence to human mu-
cosal epithelial cells, and virulence to murines.(16)
The extracellular acid proteinase termed proteinase A was
described for the first time in C. albicans in 1964.(17) Some of
the acid proteinases secreted by certain yeast species of the
genus Candida have the capacity to degrade host proteins, such
as albumin, collagen, immunoglobulins, keratin, and hemoglo-
bin(18–22) and may have a pathogenic effect depending on the
conditions of the host organism. The properties of acid pro-
teinases from C. albicans have been partially elucidated through
studies conducted by several investigators.(23,24) However, the
purification and characterization of an aspartyl proteinase se-
creted in C. albicans culture filtrates could only be obtained in
1997, by Na and collaborators.(25) Subsequently, these au-
thors(26) produced a monoclonal antibody called CAP1, which
detected the proteinase secreted by different C. albicans strains,
but not the proteinases of other Candida species. In a later study,
these authors reported that CAP1 is capable of detecting the
acid proteinase that circulated in serum from patients.(27)
In the present work, we report the purification of an as-
partyl proteinase from C. albicans, its biochemical charac-
terization, and use in mice immunization to obtain monoclo-




Thirteen Candida albicans and C. dubliniensis strains among
those available from the Fungus Culture Collection of FOP/
UNICAMP’s Microbiology and Immunology Laboratory, and
those kindly made available by Dr. Claudete Rodrigues de Paula
(Instituto de Ciências Biomédicas [ICB] Universidade de São
Paulo/SP), previously isolated from the oral cavity of patients,
were characterized by CHROMagar Candida® (Probac do
Brasil, São Paulo, Brazil), by formation of chlamydospores in
rice Agar-Tween 80 medium, and by formation of germ tubes
in normal rabbit serum.(28) In order to identify acid proteinase-
secreting strains, Candida spp. samples were inoculated in
YNB-BSA Agar medium, containing 0.2% bovine serum albu-
min (BSA; Sigma, St. Louis, MO), 1.45 g Yeast Nitrogen Base
(YNB; ammonium sulfate- and amino acid-free; DIFCO, De-
troit, MI), supplemented with 2% glucose (MERCK, White-
house Station, NJ) and 2% agar (MERCK), at pH 4.0, and in-
cubated at 37°C for 72 hours. The presence of the enzyme was
detected by the formation of an opaque halo around the yeast
colony, and enzymatic activity (Pz) was determined according
to indications of Price et al.(29) Except for C. albicans strain
ICB-158 and C. dubliniensis strain ICB-159, which were used
as negative controls, the other Candida strains showed strongly
positive enzymatic activity in acid medium. Sample type 12-A
of C. albicans was selected for the production and purification
of acid proteinase, since it was the best serologically charac-
terized strain in our collection. The 12-A strain was initially
grown in YPD liquid medium containing yeast extract at 1%
(w/v), peptone at 1% (w/v), and dextrose at 2% (w/v), until an
optical density (OD) at 660 nm equal to 1.0 was obtained. The
yeasts were settled by centrifugation, resuspended to the initial
volume in YNB-BSA liquid medium and incubated for 48 hours
at 30°C. The culture supernatants were collected by centrifu-
gation and sterilized by filtration through a 0.22-m membrane
(Millex, Millipore, Billerica, MA) for subsequent purification
of the acid proteinase.
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Mice
Female BALB/c mice were supplied by CEMIB (Centro
Multinstitucional de Investigações Biológicas), UNICAMP,
and maintained in our facilities under specific pathogen-free
conditions, with autoclaved food and water ad libitum. Mice
were used for immunizations at the age of 8 weeks. The Insti-
tutional Committee for Ethics in Animal Experimentation ap-
proved this study.
C. albicans acid proteinase purification
The C. albicans strain 12-A culture filtrate was used for pu-
rification of an acid proteinase according to indications of Na
and collaborators,(25) with modifications. In short, the proteins
were precipitated by the addition of ammonium sulfate at 75%
(w/v) to the culture filtrate. The precipitate was dissolved in 50
mM sodium phosphate buffer solution, pH 6.5, and desalted in
a Sephadex G-25 column (Sigma), previously equilibrated with
the same buffer. Next, the mixture of proteins was chro-
matographed in a DEAE-Sepharose Fast Flow column, previ-
ously equilibrated with the 50 mM phosphate buffer, pH 6.5,
and the fractions were eluted with a gradient of 150 to 400 mM
NaCl, at a flow rate of 40 mL/hr; aliquots (3.0 mL per tube)
were collected. Absorbances at 280 nm and enzymatic activity
on BSA were monitored for each fraction collected. Chro-
matographic fractions that showed enzymatic activity were
pooled, submitted to dialysis against deionized water and then
freeze dried. A 5 mg-aliquot of the freeze dried powder was re-
suspended in 240 L Tris-NaCl buffer (25 mM Tris, 10 mM
NaCl), pH 7.0, and injected into a column containing agarose gel
(Superose 12/30 HR-Pharmacia Biotech, Uppsala, Sweden), pre-
viously equilibrated with the same buffer and attached to a high-
performance liquid chromatography (HPLC) system (AKTA-pu-
rifier, Pharmacia Biotech). Elution of proteins was performed at
a flow rate of 0.5 mL/min and monitored at 210, 220, and 280
nm, using the UNICORN 3.00 software. Fractions showing en-
zymatic activity were pooled and the protein concentration in the
pool was determined by Bradford’s method.(30)
Enzymatic activity and proteinase inhibition assay
Enzymatic activity was determined by digestion of the BSA
substrate, according to Crandall and Edwards(17) and was con-
sidered positive for OD280nm values equal to or higher than 0.03.
In short, 270 L BSA at 1% (w/v) in 50 mM KCl buffer, pH
2.5 were added to each 30 L of solution containing the en-
zyme, and the mixture was incubated at 37°C for 2 hours. The
enzymatic reaction was stopped by the addition of 700 L 10%
trichloroacetic acid (TCA) (w/v), at 4°C. The precipitated pro-
tein was removed by centrifugation at 12,500g for 5 minutes.
Proteolysis was monitored by observing the OD280nm increase
in the supernatant, and one enzymatic activity unit was defined
as the amount of enzyme required to increase OD by 0.1 unit.
The enzymatic activity assays were repeated in the presence of
pepstatin A, a pepstatin-type proteinase inhibitor, as indicated
by Na et al.(25)
Polyacrylamide gel electrophoresis
Fractions containing the acid proteinase were analyzed by
polyacrylamide gel electrophoresis at 10% (w/v) in the pres-
ence of SDS-PAGE, according to Laemmli.(31) The proteins
used as reference standards were: phosphorylase b, 97 kd; BSA,
66 kd; ovoalbumin, 45 kd; carbonic anhydrase, 30 kd; trypsin
inhibitor, 20.1 kd; and lysozyme, 14.4 kd (low molecular weight
standard, LMW; Pharmacia Biotech). After running the elec-
trophoresis, the gels were stained with silver nitrate, according
to Blum et al.(32)
Enzymatic activity in polyacrylamide gel
Polyacrylamide gels at 10% containing SDS were copoly-
merized with 1.6 mg/mL gelatin or BSA (Sigma). The chro-
matography fractions containing the C. albicans proteinase
were diluted in reducing buffer and separated by electrophore-
sis as described above. Next, the gels were soaked in Triton X-
100 solution at 2% (Sigma) and then dipped into the 10 mM
Tris-HCl buffer, containing 5 mM CaCl2, pH 8.0, or in 50 mM
KCl-HCl buffer, pH 2.5 to activate the enzyme. After incuba-
tion at 37°C for 16 hours, the gels were stained with 1%
Coomassie brilliant blue R-250 in 50% methanol and 10%
acetic acid.
Immunization
BALBc mice were immunized by intraperitoneal injection
of 100 g purified proteinase emulsified with 50% complete
Freund’s adjuvant (Sigma). On days 20 and 30 after the first
injection, each animal received booster doses consisting of 50
g antigen diluted in saline solution via intraperitoneal injec-
tion. On day 33, the presence of specific antibodies in mouse
sera was investigated by indirect ELISA. The preimmune sera
of those animals were used as negative controls in the ELISA
reactions.
Obtaining and cloning hybridomas
A cell fusion experiment to obtain hybridomas was carried
out following the directions of de St. Groth and Scheideger.(33)
In short, the mice immunized with the purified proteinase were
euthanized, their spleens were aseptically removed and macer-
ated to obtain a cell suspension in complete culture medium
(RPMI-1640 medium [Sigma] containing 10% fetal bovine
serum [Nutricell, São Paulo, Brasil], 2 g/L sodium bicarbonate,
2 g/L HEPES (N-[2-Hydroxyethyl] piperazine-N-[2-ethane-
sulfonic acid]) [Sigma], and 2 L/L 2 -mercaptoethanol
[Merck]). After washing with saline solution buffered with 50
mM sodium phosphate, pH 7.2 (phosphate-buffered saline
[PBS]), containing 0.4 g/L potassium chloride, 2 g/L glucose
and 0.01 g/L phenol red, the pellet formed by 1  108 spleen
cells and 2  107 SP2 Ag14/0 myeloma cells(34) was slowly re-
suspended in 1 mL 50% polyethylene glycol (PEG 1500;
MERCK) and 10% dimethyl sulfoxide (DMSO; Sigma) in
saline solution, and kept under agitation for 1 minute, at room
temperature. Next, the cell suspension was kept at 37°C, for 90
seconds, under agitation. The suspension was then slowly di-
luted by adding 20 mL PBS, pH 7.2 during 2 minutes. The vol-
ume was completed to 50 mL with PBS pH 7.2 and the sus-
pension was centrifuged at 200g for 10 minutes. Finally, the
pellet containing the fused cells was resuspended in 100 mL
HAT medium [RPMI1640 medium containing: 20% SFB, 0.136
mg/L hypoxhantine (Sigma), 0.03 mg/L aminopterine (Sigma),
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and 0.038 mg/L thymidine (Sigma)] and distributed through
four 24-well culture plates (1 mL/well), which were maintained
at 37°C in an incubator with 5% CO2. Approximately 10 days
after cell fusion, the supernatants from the culture wells con-
taining hybridomas were tested for the presence of anti-SAP
antibodies by indirect ELISA, using the purified enzyme as anti-
gen (2 g/mL; 50 L per well), as previously described.(35)
Positive cultures in the ELISA tests were cloned by limiting di-
lution in 96-well culture plates (Corning, Corning, NY). All
anti-SAP monoclonal antibody secreting hybridomas were sub-
sequently expanded in T25 and T75 culture flasks, and some
were inoculated into BALB/c mice to obtain ascitic fluid con-
taining the monoclonal antibodies.(35) The hybridomas obtained
in all stages after fusion were preserved in liquid nitrogen.
Determination of MAb immunoglobulin isotypes
Immunoglobulin isotyping of MAbs anti-SAP was per-
formed by ELISA using the supernatants of hybridoma cultures
and the ImmunoPure Monoclonal Antibody Isotyping kit I-
HRP/ABTS (Pierce, Rockford, IL; anti-IgG1, anti-IgG2a, anti-
IgG2b, anti-IgG3, anti-IgA, and anti-IgM). Reading was per-
formed at 405 nm, considering OD values  0.8 as positive
results, according to the manufacturer’s instructions.
MAb purification and conjugation with biotin
Ascites containing anti-SAP MAbs were purified by affinity
chromatography in Sepharose–Protein G (Sigma), as indicated
by Akerstrom et al.,(36) with modifications. In short, 5 mL as-
cites were equilibrated with 100 mM dibasic sodium phosphate
solution until pH 8.0 and then applied to a column containing
4 mL adsorbent gel. After the mixture was homogenized and
incubated for 30 minutes, the immunoglobulins adsorbed to the
protein G were eluted at a flow rate of 30 mL/hr with 100 mM
glycine-HCl buffer, pH 2.8, in 2.5 mL aliquots, which were col-
lected in tubes containing 1 M Tris-HCL buffer, pH 8.5, in ice
bath. Elution was monitored in a spectrophotometer (DV-65,
Beckman Instruments, Inc., Palo Alto, CA) at 280 nm, and frac-
tions with OD higher than 0.3 were pooled, submitted to dial-
ysis against PBS pH 7.2, and protein concentration was deter-
mined by Lowry’s method modified by Hartree.(37)
Aliquots (1 mg) from each purified MAb were dissolved in
1 mL 20 mM sodium borate buffer, pH 9.0, and submitted to
dialysis against the same buffer, at 4°C for 18 h. Next, 200 L
of a biotin succinimide solution (Sigma) were added to the an-
tibody solution and the mixture was incubated for 4 hours, in
the dark. Unbound biotin was removed from the protein solu-
tion by dialysis against PBS at 4°C for 18 hours. The biotiny-
lated antibodies were diluted with buffered glycerin (v:v) and
stored at 20°C until used in the capture ELISA tests.
Western blot
Samples containing Candida spp. acid proteinase were sub-
mitted to SDS-PAGE as described above, and then the proteins
were transferred from the gel to 0.45 m nitrocellulose mem-
branes according to indications by Towbin et al.,(38) using the
Mini Transblot II system (Bio-Rad, Hercules, CA). Next, the
membranes were washed five times with PBS containing 0.05%
Tween 20 (PBST) and then immersed into the PBST blocking
solution containing 5% skimmed milk (PBST-SM) for 1 hour
at room temperature. The membranes were washed again, cut
into strips, and incubated with culture supernatants from the hy-
bridomas or with ascites serially diluted in PBST-SM contain-
ing 2% normal rabbit serum for 1 hour at room temperature and
overnight at 4°C. The strips were washed with PBST and in-
cubated for 2 hours at room temperature with the mouse per-
oxidase-conjugated anti-IgG (1:250) in PBST-SM containing
2% normal rabbit serum. After another washing cycle, the re-
actions were developed with 0.03% H2O2 and 0.5 mg/mL 3,3-
diaminobenzidine (DAB) in 0.05 M Tris-HCl buffer, pH 7.4
until bands appeared. The reaction was stopped with tap water.
Capture ELISA
Fifty microliters of purified MAb, diluted in 50 mM 0.1 M
sodium carbonate-bicarbonate buffer, pH 9.2, were added to
each well of 96-well polystyrene, flat-bottom plates (Greiner,
Monroe, NC), and the plates were incubated for 1 hour at 37°C
and overnight at 4°C. After washing with PBST, 200 L of a
block solution (PBS-5% SM) were added to each well, and
plates were incubated for 1 hour at 37°C. After a new washing
cycle, 50 L per well of serial proteinase dilutions in PBST-
2% SM were added with two replications and plates were in-
cubated for 2 hours at 37°C. After washing, 50 L of the bio-
tinylated MAbs properly diluted in PBS-2% SM were added,
and plates were incubated for another 2 hours at 37°C. After
washing, 50 L of a peroxidase-conjugated streptavidin solu-
tion (Sigma) diluted at 1:200 in PBS-2% SM were added to
each well, followed by incubation of the plates for 1 hour at
37°C. After another washing cycle, development was accom-
plished by adding substrate (0.03% H2O2 and 0.04% or-
thophenylendiamine in 50 mM citric acid/disodium hydrogen
phosphate buffer, pH 5.5) to each well. After 30 minutes in the
dark, the reaction was stopped by adding 25 L of 4 N H2SO4
to the wells, and absorbances were read at 492 nm (Multiskan
MS, Labsystems, Helsinki, Finland).
Statistical analysis
Student’s t test was used for comparisons between groups.
Variations were considered statistically significant for p val-
ues  0.05 in analyses performed with the GraphPad Prism
Software.
RESULTS
Purification of an extracellular acid proteinase
An extracellular acid proteinase was purified from the C. al-
bicans strain A-12 culture supernatant in three steps, which in-
cluded precipitation with ammonium sulfate at 75%, DEAE ion
exchange chromatography, and Sepharose 12 molecular exclu-
sion chromatography. Figure 1 illustrates the results obtained
in one of these experiments, showing absorbance at 280 nm and
the enzymatic activity of fractions eluted in each purification
stage. It can be observed that after DEAE chromatography, en-
zymatic activity on BSA was recovered in fractions that were
eluted around 300 mM NaCl of a linear NaCl elution gradient
between 150 and 400 mM (Fig. 1A). These fractions were
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pooled and freeze-dried after dialysis against water. A sample
containing 5 mg of the freeze-dried powder was resuspended
and then chromatographed in molecular exclusion resin and en-
zymatic activity was recovered in fractions eluted at a volume
between 10 and 15 mL Sepharose 12 (Fig. 1B). The purified
fraction was eluted from Sepharose at the range corresponding
to proteins with a 43-kd molecular mass. However, the SDS-
PAGE analysis of the purified fraction revealed the presence of
a homogeneous silver-stained protein band with a 41-kd mass,
which exhibited enzymatic activity over BSA copolymerized
with polyacrylamide gel at pH 2.5, but not with collagen or any
of the proteins tested at pH 8.0 (inserts in Fig. 1B). The enzy-
matic activity of the fraction purified by these procedures was
inhibited by about 56% in the 1.46 M pepstatin A treatment
at a 10:1 proteinase:inhibitor ratio.
Obtaining anti-SAP hybridomas
BALB/c mice were immunized with the purified enzyme and
when anti-SAP serum antibodies reached titers around 1:6400,
their spleen cells were used as a source of immune B-lympho-
cytes in fusion experiments to obtain anti-SAP MAb secreting
hybridomas. In the first cultivation step after fusion, all wells
in the four 24-well plates showed growing hybridomas (100%
growth), among which seven revealed the presence of anti-SAP
antibodies in their supernatants (7%), as demonstrated by indi-
rect ELISA. The hybridomas in the seven positive cultures were
cloned by limiting dilution in 96-well plates and at the end of
the selection process 19 anti-SAP monoclonal antibody secret-
ing hybridomas were obtained, all of the IgG1 kappa () iso-
type (Table 1). According to the position they occupied in the
FIG. 1. Candida albicans extracellular acid proteinase purification. Proteins resulting from the precipitation of 2 L of C. albi-
cans 12-A culture broth with 75% ammonium sulfate were sequentially chromatographed on ion exchange DEAE cellulose (A)
and molecular exclusion sepharose columns (B) as detailed in Materials and Methods. Elution of chromatographic fractions was
accompanied by absorbance at 289 nm and by enzymatic activity over bovine serum albumin (BSA) at pH 2.5. Fractions con-
taining acid proteinase were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (insert a) or
with the protein substrates incorporated into the gel (zymograms, insert b). This experiment is representative of three other ex-
periments conducted separately.
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TABLE 1. GENERATION OF ANTI-SAP, MAb-PRODUCING HYBRIDOMAS
Fusion Positive MAb
plates cultures Hybridoma clonesa isotypesb
1 3/121 1D6B5, 1D6E9, 1D6F5, 1D6G3 IgG1 
1B1B3 (MAP1), 1B1C2, 1B1D6, 1B1G1, 1B1G2, 1B1H4 IgG1 
ID2 ND
2 2/920 2A6B11, 2A6C9, 2A6E8 (MAP3), 2A6F6 IgG1 
2D2B1, 2D2E8, 2D2C10 (MAP2), 2D2F9, 2D2E9 IgG1 
3 1/820 3D4 ND
4 1/100 4C5 ND
aAnti-SAP producing hybridomas were screened by ELISA with purified proteinase.
bMAbs isotypes were determined by ELISA with a commercial kit (Pierce, Rockford, IL).
ND, not determined; SAP, secreted acid proteinases; MAb, monoclonal antibody; ELISA, enzyme-linked immunosorbent 
assay.
fusion and cloning plates, these hybridomas were initially
called: 1B1 (B3, C2, D6, G1, G2, H4); 1D6 (B5, E9, F5, G3);
2A6 (B11, C9, E8, F6); 2D2 (B1, E8, C10, F9, E9). In addi-
tion to these hybridomas, two cloning-plate cultures showed
anti-SAP secreting cells, but with more than one Ig isotype
(IgM, in addition to IgG1), indicating the need for recloning.
STUDY ON THE BINDING PROPERTIES OF
MONOCLONAL ANTIBODIES TO SAP
One representative of each of the four anti-SAP MAb-se-
creting hybridoma families (1B1B3, 1D6E9, 2A6E8, 2D2C10)
were expanded as ascitic tumors in the peritoneal cavity of
BALB/c mice to obtain a mass of monoclonal antibodies to be
purified, biotinylated, and studied in ELISA- and Western blot-
type immunoenzymatic assays. Different purified MAb combi-
nations were used as capture or detection antibodies (biotinyl-
ated antibodies) in the ELISA tests, at concentrations of 10 or
100 g/mL. Figure 2 shows that antibodies 1B1B3 (MAP1) and
2D2C10 (MAP2), used as capture antibodies, and biotinylated
2A6E8 (MAP3) were able to detect the purified SAP enzyme
at protein concentrations from 32 ng/mL. These MAbs were
also capable of detecting the enzyme in C. albicans and C.
dubliniensis crude extract preparations in ELISA assays at pro-
tein concentrations from 64 ng/mL (data not shown).
The proteins contained in the C. albicans purified fraction
and in crude C. albicans or C. dubliniensis extracts were sep-
arated by electrophoresis in SDS-PAGE minigels and then
transferred to nitrocellulose membranes. The nitrocellulose
membranes were cut into strips and reacted with the culture su-
pernatants or with ascites containing MAbs. Figure 3 illustrates
results when MAbs 1B1B3 (MAP1), 1D6E9, 2A6E8 (MAP3),
and 2D2C10 (MAP2) were used as supernatants (1:400) or as-
cites (1:1600) in the reactions involving C. albicans purified
SAP (Fig. 3A), C. albicans strain 12-A crude extract (Fig. 3B),
or C. dubliniensis strain 778 crude extract (Fig. 3C). The anti-
bodies of any of the two sources used showed the same reac-
tion profile with Candida spp proteins, with recognition of one
41-kd band. In the purified enzyme preparations, other bands
besides the 41 kd could be observed after reaction with the an-
tibodies, suggesting the presence of autodegradation compo-
nents of the enzyme itself.
DISCUSSION
Among the species in the genus Candida, Candida albicans
is considered the most important opportunistic pathogen in hu-
mans. This microorganism invades the mucosa causing can-
didiasis, a fungal infection with different degrees of severity.(5)
One of the most important virulence factors associated with in-
vasive candidiasis are extracellular acid proteinases, hydrolytic
enzymes produced by Candida,(5,39) which allow the proteolytic
invasion of tissues by these yeasts and interfere with host cell
membrane integrity, leading to dysfunctions of their normal ac-
tivities.(4,39,40) The acid proteinase seems to facilitate the ad-
herence, colonization, growth, and invasion of these microor-
ganisms on the skin and mucosae.(19,41)
Consequently, the production of extracellular proteolytic en-
zymes may serve as a pathogenicity marker for these microor-
ganisms.(42) A high enzymatic activity of the acid proteinase on
albumin (BSA) in solid medium was observed in 11 of the 13
Candida strains studied in the present work. C. albicans strain
ICB-158 and C. dubliniensis strain ICB-159 were exceptions,
but these strains are known to not produce acid proteinase. SDS-
PAGE of the purified proteinases showed a protein band of ap-
proximately 41 kd, and zymograms showed that the 41-kd band
had enzymatic activity only on BSA, at pH 2.5.
The C. albicans acid proteinase has been considered an
“aggressin,” as a result of its capacity to degrade host pro-
teins in acid microenvironments.(39) Corroborating our re-
sults, an acid aspartyl proteinase isolated from C. albicans
was capable of degrading collagen and BSA, with maximum
enzymatic activity at pH values between 2.0 and 3.5 (acid)
and irreversible denaturation at alkaline pH values.(25) How-
ever, the proteinase isolated here was only active on BSA,
and was not capable of degrading collagen, even after a 
16-hour incubation period. Data from the literature show that
the extracellular proteolytic activity of C. albicans is strongly
associated with enzymes of the aspartyl proteinase
type,(18–22,43–46) which exhibit biochemical properties simi-
lar to pepsin and cathepsin, enzymes sensitive to treatment
with reduced concentrations of pepstatin A.(47) The purified
acid proteinase in this work also had its activity in acid pH
dramatically reduced by treatment with 1.46 M pepstatin A,
indicating it is related to the aspartyl acid proteases (SAP)
described in C. albicans.
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Although they were described more than two decades ago, C.
albicans extracellular acid proteinases have not yet been well char-
acterized. The species C. albicans can produce several aspartyl
proteinase isoforms, coded by approximately 10 distinct genes,(42)
some of which are not yet characterized from a biochemical and
immunochemical point of view. Our results suggest that the en-
zyme purified in this work shares several properties with aspartyl
proteinases, but is different from acid proteinases previously iso-
lated from C. albicans in some peculiarities.
The genetic expression of each SAP isoform seems to be as-
sociated not only with conditions of the environment where
yeasts are found, but also with stage of infection. SAP 1 and 3,
for example, present greater expression in patients with oral
candidiasis or HIV-positive patients with oropharyngeal can-
didiasis, in which they cause severe damage to the epithelium
of the mucosa.(48,49) Different SAP isoforms present distinct pH
requirements for their maximum activity.(50) The strain of C.
albicans used in this work was isolated from the oral cavity of
a patient with candidiasis and its activity at pH 2.5 makes it
more similar to SAP1 than to SAP3, since the latter is not very
active in acid pH.
Proteinases with activity at different pH ranges represent an
important adaptation toward allowing the colonization of dif-
ferent anatomic sites by C. albicans. Among yeasts of the genus
Candida, those in the species C. albicans show the highest num-
ber of genes (10 genes) of the SAP family.(51) This high num-
ber of genes may be related to the frequency of clinic isolates,
but could also be associated with a higher capacity of coloniza-
tion and consequent pathogenic potential of the species.(52)
In order to produce a highly specific reagent for the isolated
proteinase, a cell fusion experiment was conducted to obtain spe-
cific monoclonal antibody secreting hybridomas. In a single cell
fusion experiment, we obtained 19 SAP-specific monoclonal an-
tibody secreting clones. All MAbs were capable of detecting the
41 kd protein by Western blot in the preparation of purified SAP,
as well as crude 12-A C. albicans and 778 C. dubliniensis ex-
tracts. In addition to the isolated clones, two cultures in the
cloning plates showed MAbs with more than one isotype (IgM,
 and ; IgG2a,  and ), which were cryopreserved to become
sources of other anti-SAP MAbs in the future.
The aspartyl proteinases normally produced by pathogenic
Candida strains induce the production of high antibody titers
in infected patients,(25,53,54) which makes them natural candi-
dates for use as antigens in the serodiagnosis of candidiasis.
However, the detection of the enzyme itself in biologic fluids
of patients may represent an important tool in the diagnosis of
candidiasis and in following up the treatment of infected pa-
tients. For this reason, some authors have invested in the pro-
duction of highly specific MAbs for C. albicans acid proteinase
in order to develop capture assays for the enzyme in the serum
of patients.(26) Nevertheless, only one anti-SAP MAb-secreting
clone called CAP1 was obtained, which recognized a sequence
between SAP amino acids Leu27 and Glu132. The genetic
cloning products of this region and their expression in Esche-
richia coli revealed proteins with molecular masses of 34.2 and
35.3 kd, which were recognized by the MAb CAP1. In our
study, three of four anti-SAP MAbs proved effective in detect-
ing the enzyme in the ELISA assays at concentrations from 32
FIG. 2. Enzyme-linked immunosorbent assay (ELISA) for
Candida albicans acid proteinase detection (secreted acid pro-
teinases [SAP]). Monoclonal antibodies (MAbs) 1B1B3
(MAP1) and 2D2C10 (MAP2) were used as capture antibodies
at a concentration of 10 g/mL. The purified SAP fraction was
used as concentrations from 8 to 12 ng/mL. This experiment is
representative of three other experiments conducted separately.
FIG. 3. Western blot analysis of anti-secreted acid proteinase (SAP) monoclonal antibodies (MAbs). Culture supernatants and
ascitic fluids containing the anti-SAP MAbs 1B1B3 (Lanes 1 and 2), 1D6E9 (Lanes 3 and 4), 2A6E8 (Lanes 5 or 6) or 2D2C10
(Lanes 7 and 8) were used at a dilution of 1:400 and 1:1,600, respectively, for the detection of SAP in three different prepara-
tions of candida yeasts, which were transferred to nitrocellulose membrane (140 mg/channel). (A) SAP isolated from C. albi-
cans; (B) Crude extract from C. albicans; (C) Crude extract from C. dubliniensis. Pre-immune serum of mouse was used as the
negative control at a dilution of 1:50 (Lane 9). Arrows indicate SAP molecular weight (41kDa).
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ng/mL, that is, MAP1 (1B1B3) or MAP2 (2D2C10) as coat an-
tibodies and biotinylated MAP3 (2A6E8) as a detect antibody.
These antibody pairs also detected the enzyme in crude C. al-
bicans and C. dubliniensis (strain 778) extracts from 64 ng/mL.
In the immunoblottings carried out in our study we were able
to observe several bands with molecular masses smaller than
41 kd recognized by the MAbs in the purified fraction and in
the crude extracts blotted onto nitrocellulose. It is possible that
the material may have undergone autodegradation during the
enzyme handling and storage, which could explain the low de-
tection of these antigens in the ELISA-type assays.
Although more sophisticated assays have been developed to
detect differences between Candida species, such as fluores-
cence in situ hybridization using peptide nucleic acid probes
(PNA-FISH), which detects differences in the rRNA sequence
between C. albicans and C. dubliniensis(55) or the phage dis-
play technology to study the expression of surface antigens in
C. albicans,(56) methodologies that explore serologic differ-
ences between these two species, with immunologic reagents
efficient for the quick identification of these pathogens, repre-
sent a potential yet to be explored.(57–59) Thus, obtaining im-
munologic reagents such as MAbs, which recognize relevant
C. albicans or C. dubliniensis antigens, will expand the reper-
toire of potential reagents for the diagnosis and differentiation
between these related species. This is particularly desirable at
a moment when it is observed that the indiscriminate use of an-
tifungal drugs in past decades has contributed toward the ap-
pearance of azole-resistant Candida strains.(11) A precise diag-
nosis about the Candida species causing the infection will
provide orientation in the selection of the most suitable an-
timycotic agents for the patient, and will be also useful in mon-
itoring the effectiveness of the antifungal treatment.
Therefore, the hybridomas obtained in this work will be sub-
sequently analyzed as to their capacity to capture the acid pro-
teinase (SAP) present in fluids such as saliva or serum of pa-
tients colonized by different yeast species of the genus Candida,
perhaps providing a sensitive and specific assay to diagnose in-
fection by these yeasts.
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